OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
What influences the activity of Degrader−Antibody conjugates (DACs)
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 8
Yaolin Guo, Xiaoxue Li, Yang Xie, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116216-116216
Closed Access | Times Cited: 8
Showing 8 citing articles:
Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 20
Jiahao Li, Gong Chen, Haiting Zhou, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5489-5489
Open Access | Times Cited: 20
Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders
Lingying Leng, Wenbin Tu, Lin Yang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Lingying Leng, Wenbin Tu, Lin Yang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
Prodrug Approach as a Strategy to Enhance Drug Permeability
Mariana Moraes Dionysio de Souza, Ana Luísa Rodriguez Gini, Jhonnathan Alves Moura, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 297-297
Open Access
Mariana Moraes Dionysio de Souza, Ana Luísa Rodriguez Gini, Jhonnathan Alves Moura, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 297-297
Open Access
Application of Artificial Intelligence and Computational Biology in Protein Drug Development
Jiacheng Jiang, Wen Li, Weiran Huang, et al.
Pharmaceutical Fronts (2025)
Open Access
Jiacheng Jiang, Wen Li, Weiran Huang, et al.
Pharmaceutical Fronts (2025)
Open Access
Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation
Jiachan Lin, Zirui Chen, Dan Zhang, et al.
Macromolecular Rapid Communications (2025)
Closed Access
Jiachan Lin, Zirui Chen, Dan Zhang, et al.
Macromolecular Rapid Communications (2025)
Closed Access
Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives
Santanu Singh, Kajal Kachhawaha, Sumit K. Singh
Biochemical Pharmacology (2024) Vol. 225, pp. 116303-116303
Closed Access | Times Cited: 1
Santanu Singh, Kajal Kachhawaha, Sumit K. Singh
Biochemical Pharmacology (2024) Vol. 225, pp. 116303-116303
Closed Access | Times Cited: 1
Precision-engineered PROTACs minimize off-tissue effects in cancer therapy
Jianghua Shi, Luo Wang, Xuanwei Zeng, et al.
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access
Jianghua Shi, Luo Wang, Xuanwei Zeng, et al.
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access
A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment
Lei Wang, Yong Ke, Qunye He, et al.
Theranostics (2024) Vol. 15, Iss. 4, pp. 1238-1254
Open Access
Lei Wang, Yong Ke, Qunye He, et al.
Theranostics (2024) Vol. 15, Iss. 4, pp. 1238-1254
Open Access
